Microaneurysm Turnover Is a Biomarker for Diabetic Retinopathy Progression to Clinically Significant Macular Edema: Findings for Type 2 Diabetics with Nonproliferative Retinopathy

被引:80
作者
Nunes, Sandrina [1 ]
Pires, Isabel [1 ,2 ]
Rosa, Andreia [1 ,2 ]
Duarte, Lilianne [1 ]
Bernardes, Rui [1 ,3 ]
Cunha-Vaz, Jose [1 ,2 ,3 ]
机构
[1] Univ Coimbra, Fac Med, Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal
[2] Univ Coimbra, Coimbra Univ Hosp, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Fac Med, Inst Biomed Res Light & Image, Coimbra, Portugal
关键词
Microaneurysm count; Microaneurysm turnover; Microaneurysm formation rate; Microaneurysm disappearance rate; Diabetic retinopathy; Image co-registration; Color fundus photography;
D O I
10.1159/000213639
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To examine the relationship between microaneurysm turnover (formation rate), using a new semi-automatic method (MA-Tracker) based on color fundus photographs, and diabetic retinopathy (DR) progression to clinically significant macular edema (CSME). Methods: In total, 113 patients/eyes with nonproliferative DR (NPDR) were followed up every 6 months for 2 years as controls of the DR clinical trials, and by conventional general and ophthalmological care for the next 8 years (over a total of 10 years' follow-up). Microaneurysm turnover for the 2 first years was computed using the MA-Tracker. Results: The 17 patients that developed CSME over the 10 years of follow-up presented a microaneurysm formation rate of 9.2 +/- 18.2 microaneurysms/year (mean 8 SD) during the first 2 years, which was statistically higher than the eyes that did not develop CSME (0.5 +/- 1.2 microaneurysms/year, p < 0.001). These 17 patients also presented higher HbA(1C) levels at baseline (8.5 +/- 1.2%) compared to the patients who did not develop CSME (7.3 +/- 1.2%, p = 0.001). Conclusions: A high microaneurysm formation rate on color fundus photographs appears to be a good biomarker for DR progression to CSME in type 2 diabetic patients with NPDR. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:292 / 297
页数:6
相关论文
共 16 条
[1]  
[Anonymous], 1991, OPHTHALMOLOGY, V98, P823
[2]  
[Anonymous], BIOMETRICS
[3]   Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium [J].
Csaky, Karl G. ;
Richman, Elaine A. ;
Ferris, Frederick L., III .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (02) :479-489
[4]  
Cunha-Vaz Jose, 2007, Dev Ophthalmol, V39, P13, DOI 10.1159/000098497
[5]  
*EARL TREATM DIAB, 1991, OPHTHALMOLOGY S, V98, P767
[6]  
FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
[7]  
Fleiss J., 1986, Reliability of measurement: the design and analysis of clinical experiments
[8]   Disappearance and formation rates of microaneurysms in early diabetic retinopathy [J].
Hellstedt, T ;
Immonen, I .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1996, 80 (02) :135-139
[9]   The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes [J].
Hove, Marianne Norgard ;
Kristensen, Jette Kolding ;
Lauritzen, Torsten ;
Bek, Toke .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2006, 84 (05) :619-623
[10]  
KLEIN R, 1995, OPHTHALMOLOGY, V102, P7